Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis is a research paper published in Contemporary Clinical Trials (2021). On theSindex it has a DataRank of 0.400. It has been cited 5 times, with 4 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.269
From this paper's citation signal
Citation Network Contribution
0.131
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 4 citers.
NIAID NIH HHS
Grant: UM1 AI068634
NIAID NIH HHS
Grant: UM1 AI106701
Intramural CDC HHS
Grant: CC999999
NIAID NIH HHS
Grant: U01 AI068634
NIAID NIH HHS
Grant: UM1 AI068636
NIAID NIH HHS
Grant: UM1 AI069463
National Institute of Allergy and Infectious Diseases
MeSH Terms
Keywords